Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma

Journal of Clinical Oncology

Volumn 21, Issue 20, 2003, Pages 3770-3776

  Hernberg, Micaela ^a   Virkkunen, Pekka ^a   Bono, Petri ^a   Ahtinen, Henna ^a   Mäenpää, Hanna ^a   Joensuu, Heikki ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; THALIDOMIDE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; SIGNAL PEPTIDE; VASCULOTROPIN A;

ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; METASTASIS; NEUROPATHY; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; DIET THERAPY; DRUG ADMINISTRATION; DRUG SCREENING; FEMALE; KIDNEY TUMOR; MALE; MAXIMUM TOLERATED DOSE; SURVIVAL RATE; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON ALFA-2B; KIDNEY NEOPLASMS; LYMPHOKINES; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM METASTASIS; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0142119275     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.536     Document Type: Article

References (36)

1. Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002
2. Glaspy JA: Therapeutic options in the management of renal cell carcinoma. Semin Oncol 29:41-46, 2002
3. Hartmann JT, Bokemeyer C: Chemotherapy for renal cell carcinoma. Anticancer Res 19:1541-1543, 1999
4. Negrier S, Escudier B, Lasset C, et al: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma: Groupe Francais d'Immunotherapie. N Engl J Med 338:1272-1278, 1998
5. Negrier S, Maral J, Drevon M, et al: Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am 1:S93-S98, 2000 (suppl 6)
6. Igarashi H, Esumi M, Ishida H, et al: Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 95:47-53, 2002
7. Shuin T, Kondo K, Torigoe S, et al: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 54:2852-2855, 1994
8. Gunningham SP, Currie MJ, Han C, et al: Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: Regulation by the von Hippel-Lindau gene and hypoxia. Cancer Res 61:3206-3211, 2001
9. Turner KJ, Moore JW, Jones A, et al: Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62:2957-2961, 2002
10. Sato K, Tsuchiya N, Sasaki R, et al: Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J Cancer Res 90:874-879, 1999
11. Jacobsen J, Rasmuson T, Grankvist K, et al: Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 163:343-347, 2000
12. Slaton JW, Perrotte P, Inoue K, et al: Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5:2726-2734, 1999
13. Klement G, Baruchel S, Rak J, et al: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24, 2000
14. Browder T, Butterfield CE, Kraling BM, et al: Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000
15. Stephens TD, Bunde CJ, Fillmore BJ: Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 59:1489-1499, 2000
16. Little RF, Wyvill KM, Pluda JM, et al: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18:2593-2602, 2000
17. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085, 1994
18. Ching LM, Xu ZF, Gummer BH, et al: Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 72:339-343, 1995
19. Kenyon BM, Browne F, D'Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64:971-978, 1997
20. Eisen TG: Thalidomide in solid tumors: The London experience. Oncology (Huntingt) 14:17-20, 2000
21. Daliani DD, Papandreou CN, Thall PF, et al: A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95:758-765, 2002
22. Escudier B, Lassau N, Couanet D, et al: Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 13:1029-1035, 2002
23. Motzer RJ, Berg W, Ginsberg M, et al: Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20:302-306, 2002
24. Stebbing J, Benson C, Eisen T, et al: The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 85:953-958, 2001
25. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
26. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
27. Eisen T, Boshoff C, Mak I, et al: Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82:812-817, 2000
28. Minor DR, Monroe D, Damico LA, et al: A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest New Drugs 20:389-393, 2002
29. Novik Y, Dutcher JP, Larkin M, et al: Phase II study of thalidomide (T) in advanced refractory metastatic renal cell cancer (MRCC): A single institution experience. Proc Am Soc Clin Oncol 20:265a, 2001 (abstr 1057)
30. Li Z, Amato R, Papandreou C, et al: Phase II study of thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interleukin-2 (IL-2)-based therapy (Rx). Proc Am Soc Clin Oncol 20:180a, 2001 (abstr 717)
31. Kankuri M, Pelliniemi TT, Pyrhonen S, et al: Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: A phase II study. Cancer 92:761-767, 2001
32. Nathan PD, Gore ME, Eisen TG: Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol 20:1429-1430, 2002
33. Motzer RJ, Rakhit A, Thompson J, et al: Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol 13:1799-1805, 2002
34. Motzer RJ, Rakhit A, Ginsberg M, et al: Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 19:1312-1319, 2001
35. Bukowski R, Ernstoff MS, Gore ME, et al: Pegylated interferon alfa-2b treatment for patients with solid tumors: A phase I/II study. J Clin Oncol 20:3841-3849, 2002
36. Salven P, Orpana A, Joensuu H: Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 5:487-491, 1999